title: Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.
abstract: Androgen receptor (AR) signaling is essential for the initial development and progression of prostate cancer (PCa) as well as the growth and survival of castration-resistant tumors. However, AR action may be opposed by estrogen receptor beta (ERß) that responds to androgen metabolites produced in the prostate. The balance between the activity of these two receptors is not only influenced by the steroidogenic capacity of the prostatic microenvironment but also by its redox status and local paracrine signals such as transforming growth factor-beta (TGF-ß). In this review, we highlight the studies that revealed select roles for AR and ERß in distinct compartments of the prostate cancer microenvironment. We also discuss new work that identified stromal-epithelial crosstalk through TGF-ß1 signaling that drives the production of reactive oxygen species in stromal cells thereby selectively limiting the anti-tumor activity of ERß in cancer cells. Therefore, any new therapeutic approaches that seek to limit AR but enhance ERß activity in PCa, must take into account potential adaptive changes in the tumor microenvironment that utilize paracrine signals and altered redox balance to divert local androgen metabolites towards AR at the expense of ERß.
authors: Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, 3051 Fifth Avenue, Pittsburgh, PA 15260, USA. grubisha.melanie@medstudent.pitt.edu
authors: Melanie J
authors: MJ
authors: Grubisha
authors: Donald B
authors: DB
authors: DeFranco
mesh_terms: D004703:Endocrine System / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000378:metabolism*; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D019899:Paracrine Communication; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011944:Receptors, Androgen / Q000378:metabolism*; D015398:Signal Transduction; D059016:Tumor Microenvironment
chemical_list: D047629:Estrogen Receptor beta; D011944:Receptors, Androgen
references: J Urol. 2004 Oct;172(4 Pt 1):1399-403
references: 15371854
references: Clin Nephrol. 1999 Feb;51(2):67-72
references: 10069640
references: Pathology. 2007 Jun;39(3):305-18
references: 17558857
references: Baillieres Clin Endocrinol Metab. 1998 Oct;12(3):501-6
references: 10332569
references: Int J Cancer. 1998 Aug 12;77(4):511-5
references: 9679750
references: Mol Endocrinol. 2012 Jun;26(6):940-54
references: 22593181
references: Am J Pathol. 2006 Jun;168(6):1869-78
references: 16723702
references: Cancer Epidemiol. 2010 Jun;34(3):316-22
references: 20409773
references: Breast Cancer Res. 2008;10(4):R61
references: 18631401
references: Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12182-7
references: 18723679
references: Cancer Cell. 2010 Apr 13;17(4):319-32
references: 20385358
references: J Nutr. 1995 Mar;125(3 Suppl):757S-770S
references: 7884562
references: Mol Endocrinol. 1995 Feb;9(2):208-18
references: 7776971
references: J Natl Cancer Inst. 1998 Jun 17;90(12):911-5
references: 9637140
references: J Biol Chem. 2002 Aug 9;277(32):29304-14
references: 12015328
references: Trends Endocrinol Metab. 2010 May;21(5):315-24
references: 20138542
references: Cancer Res. 2004 Jan 15;64(2):765-71
references: 14744796
references: Cancer Res. 2010 Feb 1;70(3):1256-64
references: 20086173
references: Urology. 2007 Aug;70(2):374-9
references: 17826523
references: Curr Med Chem. 2011;18(17):2554-65
references: 21568892
references: Cell Signal. 2011 Jun;23(6):1017-21
references: 21130868
references: Cancer Metastasis Rev. 1998-1999;17(4):383-90
references: 10453282
references: Prostate. 2003 May 15;55(3):180-6
references: 12692783
references: Cell. 2011 May 13;145(4):584-95
references: 21565615
references: J Clin Invest. 2000 Jun;105(11):1589-94
references: 10841517
references: Endocr Relat Cancer. 2010 Jul 28;17(3):731-42
references: 20562232
references: Biochemistry. 2000 Jul 25;39(29):8406-17
references: 10913246
references: J Am Soc Mass Spectrom. 2005 Dec;16(12):2017-26
references: 16246571
references: Cancer Res. 2005 Jun 15;65(12):5445-53
references: 15958594
references: Urology. 2001 Aug;58(2 Suppl 1):127-31
references: 11502467
references: Recent Results Cancer Res. 2007;175:211-37
references: 17432562
references: Cancer Res. 1994 Oct 15;54(20):5474-8
references: 7522959
references: Endocrinology. 2001 Jun;142(6):2458-67
references: 11356695
references: Curr Med Chem. 2008;15(23):2366-79
references: 18855666
references: Cancer Res. 2008 Mar 15;68(6):1777-85
references: 18339858
references: J Mol Endocrinol. 2007 Sep;39(3):183-8
references: 17766643
references: Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):223-8
references: 18471781
references: J Clin Endocrinol Metab. 2004 May;89(5):2434-41
references: 15126575
references: Cancer Treat Res. 1998;94:69-87
references: 9587683
references: Prostate. 2003 Mar 1;54(4):275-89
references: 12539226
references: J Nutr. 2000 Mar;130(3):658S-9S
references: 10702603
references: Mol Cell Endocrinol. 1998 Nov 25;146(1-2):151-61
references: 10022773
references: Clin Cancer Res. 2011 Apr 1;17(7):1649-57
references: 21372223
references: Nat Rev Cancer. 2011 Jul 22;11(8):597-608
references: 21779010
references: Nat Rev Urol. 2011 May 31;8(7):378-84
references: 21629218
references: Endocr Relat Cancer. 2011 Aug 30;18(5):R175-82
references: 21712345